4hydroxytamoxifen

4-Hydroxytamoxifen (ICI 79280) 是 Tamoxifen 的活性代谢产物，是一种雌激素受体调节剂 (SERM)，具有选择性和口服有效性。4-Hydroxytamoxifen 具有抗肿瘤活性，可用于乳腺癌的研究。

(E)-4-Hydroxytamoxifen is a less active isomer of (Z)-4-hydroxytamoxifen and also is an estrogen receptor modulator.

(E/Z)-4-Hydroxytamoxifen (Afimoxifene) 是一种新的雌激素抑制剂，多用于多种雌激素依赖性疾病的研究，包括周期性乳房疼痛和男性乳房发育症。

It is a metabolite of tamoxifen and an estrogen receptor modulator.

4'-Hydroxytamoxifen TFA, 作为Tamoxifen的一个代谢物盐形态，对ER具有比Tamoxifen更高的亲和性。此化合物在人类子宫内膜腺癌细胞中能够诱导非凋亡细胞毒性。

Endoxifen ((E/Z)-Endoxifen) 是 Tamoxifen 的关键活性代谢物，能抑制芳香酶的活性，与雌激素受体有较高的亲和力和特异性。它有潜力研究乳腺癌。

SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC(50) values between 5.0 and 68.1 nmol/l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.

(E)-4-Hydroxytamoxifen-d5 ((E)-Afimoxifene-d5) 是 (E)-4-Hydroxytamoxifen 的氘取代形式。(E)-4-Hydroxytamoxifen ((E)-Afimoxifene) 是 (Z)-4-hydroxytamoxifen 的低活性异构体，并作为雌激素受体 (estrogen receptor) 的调节剂。